CD84 is a Suppressor of T and B Cell Activation during Mycobacterium tuberculosis Pathogenesis

Abstract excerpt

Immune checkpoint therapies, such as targeting checkpoints like PD-1/PD-L1, have proved successful in cancer therapy and can reinvigorate immune responses. The potential of this approach for treating chronic infectious diseases like TB has been recognized, but a lack of suitable immunotherapeutic targets, i.e., immune cell inhibitory receptors that trigger immunosuppression specifically during Mycobacterium...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Mycobacterium research and diagnosis
• Share to Tuberculosis Research and Epidemiology